NUVISAN has in-depth experience with various types of first in human (FiH) and dose escalation studies (e.g., single and multiple ascending dose, dose finding) following parallel or crossover designs. We are able to enroll both healthy volunteers, special populations and patients. For your FIH studies, NUVISAN conveniently hosts bioanalysis, immunology and safety laboratories under one roof, at our Neu Ulm site.
